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Once Daily Beta-Blocker in Hypertension - Oxprenolol
Slow-Release
R D Gordon, MD, FRACP, M Ziesak, SRN, W S Rowe, MBBS, FRACP, C R Strakosch, MD,
FRACP and GRow, MBlJS, FRACP, University Department of Medicine and Endocrine-
Hypertension Clinic, Repatriation Hospital, Greens/opes, Queens/and, 4120, Australia
In a within-patient comparison ofconventional oxprenolol administered twice
daily with slow-release oxprenolol administered once daily in the treatment
of hypertension, twenty patients previously responsive to beta-blockers took
each formulation for 4 weeks, after wash-out periods off beta-blocker of 2
weeks' duration. The order of administration of the two forms was
randomized, and sixteen patients continued medication with cyclopenthia-
zide 0·5 mg daily. Blood pressure levels at the end of the 4-week treatment
periods were compared with levels at the end ofthe preceding 2-week wash-
out periods.
Both formulations lowered blood pressure and pulse rate significantly.
There was no difference in their effects on pulse rate or on blood pressure,
whether measured by the doctors using standard sphygmomanometers or by
the hypertension sister using a random-zero sphygmomanometer. In four
patients who measured their own blood pressures at home each morning
(before medications), afternoon and night, mean levels were similar with the
twoformulations. Bothformulations were very well tolerated.
Introduction
The plasma half-life of beta-blockers varies
from approximately 1 to 9 hours (Petrie et a/
1CJ76, McAinsh 1977), and their effect on
heart rate (resting or stimulated) decreases
significantly within 24 hours of administration.
In spite of this, various beta-blockers have
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been administered with good effect once daily
in the treatment of arterial hypertension
(Gordon 1975, Gordon 1976, Frithz 1976,
Douglas-Jones & Cruikshank 1976,
Reybrouck et a/ 1978), with the advantages of
ease of administration and improved patient
compliance (Gatley 1968, Persoff, Rowbury &
Mason 1978, Haynes et a/ 1976). If the patient
is already receiving a thiazide diuretic once
daily, both medications may conveniently be
administered together.
The half-life of oxprenolol is 1·3 hours,
while its pharmacological effects last for 8-12
hours (Brunner, Imhof & Jack 1975). A slow-
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release (S-R) formulation has been developed.
The peak plasma concentration achieved by S-
R in a dose of 160 mg is similar to that
achieved by 80 mg of conventional oxprenolol
(C-O), but high concentrations persist for
much longer (West et al 1976). This paper
describes a within-patient comparison of S-R
once daily and C-O twice daily in the out-
patient treatment of hypertension.
Methods
Throughout, diastolic pressure refers to
Korotkoff phase V, disappearance of sound.
Patients were selected from among those
attending an afternoon hospital out-patient
hypertension clinic whose blood pressure had
previously been well controlled by a beta-
blocker, with or without a thiazide diuretic.
Patients with past or present angina pectoris,
heart failure, asthma, diabetes mellitus requiring
insulin, clinical gout, cerebrovascular disease,
plasma creatinine greater than 0·2 mmol/l or
plasma potassium less than 3·0 mmol/l were
excluded. Only patients with a good drug
compliance record and untreated diastolic
blood pressure less than 126 mm Hg were
accepted. The beta-blocking drug which they
were receiving was ceased for 2 weeks (first
wash-out period). If diastolic blood pressure
was then 100-125 mm Hg in the supine
position after 5 minutes rest (mean of 4
readings on 2 consecutive occasions measured
by MZ using a Hawkesley random-zero
sphygmomanometer) they entered the trial,
and were randomly allocated to one of two
equal groups. This allocation determined
whether they received C-O or S-R first.
Twenty patients aged 26 to 71 years (mean, 56
years) entered and completed the study.
Table 1
Study protocol
7
Twelve were males. Sixteen were already
receiving cyclopenthiazide 0·5 mg daily and
this was continued.
Patients received either 80 mg C-O
immediately before breakfast and immedi-
ately before the evening meal, or 160 mg S-R
immediately before breakfast. After 4 weeks
the oxprenolol was ceased, and after 2 weeks
with no beta-blocker (second wash-out period)
the alternative form was administered for 4
weeks (Table 1). Patients were seen each 2
weeks during medication periods, and each
4-7 days during wash-out periods.
Blood pressure was measured: (1) in twenty
patients by a Hawkesley random-zero
sphygmomanometer by one observer (MZ)
after 5 minutes supine rest and again after 2
minutes standing. These measurements were
repeated, and the results averaged; (2) in
eighteen patients lying and standing by one of
four doctors (RG, WR, CS, GR) using a
standard mercury sphygmomanometer; and
(3) in four patients by the patients themselves.
They had been trained to use modified
sphygmomanometers ('Autosfig' - Propper
Manufacturing Company, New York, or
'Teru-Ace' Mark IV Home Blood Pressure Kit,
Japan) with stethoscope diaphragm built into
the cuff, and an aneroid gauge which was
regularly checked against a mercury gauge.
Blood pressure was measured after 5 minutes
supine, and again after 2 minutes upright (a)
on first awakening (b) on first arriving home
from work (5-6.30 p.m.) and (c) immediately
before retiring at night. These times
correspond to 23, 10 and 14 hours after S-R
and 12, 10 and 3 hours after C-O.
Clinic blood pressures were measured
between 1.30 p.m. and 3.00 p.m., 5·5 to 8·5
hours after the last dose of oxprenoloI. .
Time (weeks) 2 4 2 4
Beta-blocker Nil (wash-out) Oxprenolol 80 mg Nil (wash-out) Oxprenolol 80 mg
twice daily or twice daily or
Oxprenolol S-R Oxprenolol S-R
160 mg once daily 160 mg once daily
± Cyclopenthiazide 0·5 mg mane
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8Pulse rate lying and standing was measured
by one observer (MZ) at the time of blood
pressure measurement.
Biochemistry. Plasma creatinine, urea, uric
acid, sodium, potassium and calcium were
measured in the Hospital Biochemistry
Department by routine methods at the
conclusion of each wash-out and treatment
period. Plasma glucose, cholesterol and
triglycerides were measured in the Hospital
Biochemistry Department at the conclusion of
the first wash-out period and at the conclusion
of each period of oxprenolol administration .
. Other tests. Slit lamp examination of the
eyes, ECG and ANF tests were performed
before commencing oxprenolol and at the
conclusion of each period of oxprenolol
administration.
Tolerability of the drug was assessed at
each visit by questionnaire and direct enquiry.
Statistics. Blood pressure levels at the end
of the 4-week treatment periods were
compared with levels at the end of preceding
'wash-out' periods. The effects of the two
formulations (change from 'wash-out' period
and also absolute level achieved) were
compared by the Students' 't' test for paired
data. Means and standard errors of the means
are shown in the text and the Figures unless
otherwise indicated.
Results
Blood pressure. Mean BP fell significantly by
21·S/IS·7mmHg lying and 19·3/13 mm Hg
standing during treatment with CoO and by
23·9/13 mm Hg lying and 20·4/12·6 mm Hg
standing with S-R. There were no significant
differences between the BP changes or levels
achieved while receiving the two formulations,
based on either the doctors' or the sister's
measurements (Figure 1), which were
themselves not significantly different. There
were also no significant differences between
mean BP levels at the end of wash-out periods.
Home blood pressures showed remarkably
consistent patterns in individual patients (Figure
2). In one of the four patients, both systolic
and diastolic pressures, lying and standing,
were significantly higher in the morning while
receiving the S-R formulation (lowest panel,
Figure 2). In another patient (top panel), the
lying diastolic and standing systolic pressures
in the morning were significantly lower while
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receiving the S-R formulation. In the other two
patients there was no difference in morning
blood pressures while receiving the two
formulations. In two patients, pressures later
in the day were significantly lower while
receiving the S-R formulation, and in one
patient the last readings of the day were lower
while receiving the CoO formulation. There
was thus no consistent pattern for the four
patients taken together, and mean levels for
the group were almost identical in the morning
(1), afternoon (2) and night (3); for lying blood
pressure (1) CoO 134/83, S-R 134/83 (2) CoO
134/82, S-R 132/80 (3) COO 135/84, S-R
134/82 and for standing blood pressure (1)
CoO 130/93, S-R 131/94 (2) CoO 130/92, S-R
128/93 (3) CoO 131/91, S-R 131/89.
Other observations. Mean pulse rate fell
significantly (p < 0·01) and equally with each
formulation in both supine and upright
positions.
There were no significant changes in body-
weight, plasma urea, creatinine, uric acid,
sodium, potassium, calcium, cholesterol,
triglycerides, glucose, ECG or slit lamp
examination of the eyes, and no appearance of
positive ANF during the study.
Side-effects. Two patients complained of
headache while taking oxprenolol (one
receiving each formulation), two complained
of nausea (both receiving S-R), and one each
complained of dyspnoea (C-O), constipation
(S-R) and urinary frequency (C-O). In each
case the complaints were transient and in no
case was it necessary to withdraw the
oxprenoloI.
Acceptance. Most patients said that they
preferred the S-R formulation because of the
convenience of once daily administration.
Discussion
The adequacy of a single daily dose of beta"
blocker in the treatment of hypertension is best
assessed by repeated measurements spaced
throughout the 24-hour period during chronic
administration. In the present study,
measurements in the clinic, 5·5 to 8·5 hours
following the last dose of oxprenolol, showed
the slow-release formulation to be equally
effective with the conventional formulation.
The use by the hypertension sister of a
random-z.ero sphygmomanometer in order to
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Fig 1 Blood pressure levels measured by standard mercury sphygmomanometer (lower panel) or by random-zero
sphygmomanometer (upper panel) after 2 weeks without beta-blocker therapy (open bars) and again after 4 weeks'
therapy with oxprenolol in conventional (C-O) or slow-release (S-R)formulation (hatched bars).
•p <0·02 }
"p <0·01 beta-blocker vs no beta-blocker
•••p <0·001
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Fig 2 Home blood pressure levels (means of14 observations, S.E. of mean less than 1 mm Hg not shown) during the
last 2 weeks' treatment with either conventional oxprenolol twice daily (solid bars) or slow-release oxprenolol once
daily (open bars), in three males aged 25,26 and 48 years, and one female aged 58 years .
•p <0·05 }
••p <0.01 S-R vs C-O
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remove observer bias confirmed the findings
based on doctor's readings.
Home blood pressure measurement in four
patients permitted comparison of efficacy 23,
10 and 14 hours after a single daily dose of
S-R with that 12, 10 and 3 hours after the last
dose when taking C-O twice daily. The two
methods of administration produced very
similar levels of blood pressure, with no
systematic differences in efficacy at different
times of day. Millar-Craig and Raftery (1978)
reported results in one patient with essential
hypertension; intra-arterial blood pressure was
monitored continuously for 24 hours while
on no treatment and again after 7 weeks of
oxprenolol S-R 160 mg at 8 a.m.; treatment
produced a fall in blood pressure throughout
the 24 hours which was greater than the mean
fall in ten essential hypertensives who had
received 240 mg C-O daily in divided doses for
8 weeks.
In the conduct of clinical trials involving
measurement of blood pressure, a compromise
must be reached between the accuracy and
total information achieved by invasive,
ambulatory, intra-arterial monitoring and the
practicality of reproducible recordings,
preferably observer-blind, in what is often a
busy clinic situation. Home blood pressure
measurement adds another parameter which is
complementary. Because of repeated
measurement, the influence of the occasional,
atypical reading is diluted, permitting
confident interpretation of small, consistent
changes.
The excellent response to both formulations
of oxprenolol in this study is explained by
selection of patients previously shown to
respond well to beta-blockers. Inclusion of
'non-responders' to beta-blockers would have
made any differences between the two
formulations difficult to uncover. The fact that
all patients had previously been treated
successfully with a beta-blocker, together with
strict exclusion conditions, probably explains
the very low incidence of side-effects. If side-
effects increase proportionally with peak
plasma levels achieved, then S-R oxprenolol
could have an advantage over C-O, but this
question would have to be examined in a large
number of patients, not already selected for
their acceptance of beta-blocking drugs.
Oxprenolol S-R has a place on the list of beta-
11
blockers shown to be effective in single daily
dosage which already includes pindolol
(Gordon 1975, Gordon 1976, Frithz 1976},
metoprolol (Gordon 1976, Reybrouck et al
1978), propranolol (Gordon 1976) and
atenolol (Douglas-Jones & Cruikshank 1976).
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